ADVFN Logo ADVFN

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

0JGL Pci Biotech Holding Asa

51.00
0.00 (0.00%)
10 Jan 2025 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Pci Biotech Holding Asa LSE:0JGL London Ordinary Share NO0010405640 PCI BIOTECH HOLDING ORD SHS
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 51.00 400 00:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 2.99M -20.32M -0.5443 -93.70 1.9B

PCI Biotech: Invitation to second half interim 2023 results presentation

12/02/2024 8:26am

UK Regulatory


Pci Biotech Holding Asa (LSE:0JGL)
Historical Stock Chart


From Jan 2024 to Jan 2025

Click Here for more Pci Biotech Holding Asa Charts.
PCI Biotech: Invitation to second half interim 2023 results presentation

Oslo, Norway, 12 February 2024 - PCI Biotech (OSE: PCIB) invites to a webcast presentation of the company's second half 2023 interim report on Wednesday 14 February 2024, 08:30am – 09:30am CET (local time).

The presentation will be held as a live webcast and can be accessed through www.pcibiotech.com. The presentation will be held in Norwegian. There will be a Q&A session at the end of the presentation and it will be possible to post written questions through the webcast console.

The interim report and presentation will be made available on www.newsweb.no and on the company's webpage, www.pcibiotech.com, from 07.00am CET the same day.

For further information, please contact:
Ronny Skuggedal, CEO / CFO
Email: rs@pcibiotech.no
Mobile: +47 9400 5757

About PCI Biotech         
PCI Biotech is a biopharmaceutical company focussing on development and commercialisation of novel therapies and new technologies through its innovative photochemical internalisation (PCI) technology platform. PCI induces triggered endosomal release that is used to unlock the true potential of therapeutic modalities.

The fimaNAc programme utilises the proven capability of the PCI technology for intracellular delivery of nucleic acids. The technology can be used for most types of nucleic acids, ranging from oligonucleotides through mRNA and plasmids to viral vectors. The development of the fimaNAc programme is currently focussed on selected applications within bioprocessing and dermatology, well suited to the specific strengths of the PCI technology. The fimaVACC programme aims to enhance immunotherapy in cancer, by triggered endosomal release of antigens or nucleic acids encoding antigens, or immunostimulatory factors.

For further information, please visit: www.pcibiotech.com                        
Contact information: PCI Biotech Holding ASA, Ullernchausséen 64, N-0379 Oslo                 

Forward-looking statements      
This announcement may contain forward-looking statements, which as such are not historical facts, but are based upon various assumptions, many of which are based, in turn, upon further assumptions. These assumptions are inherently subject to significant known and unknown risks, uncertainties and other important factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this announcement by such forward-looking statements. PCI Biotech disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


1 Year Pci Biotech Holding Asa Chart

1 Year Pci Biotech Holding Asa Chart

1 Month Pci Biotech Holding Asa Chart

1 Month Pci Biotech Holding Asa Chart

Your Recent History

Delayed Upgrade Clock